• Gyre Therapeutics outlined a global development model anchored in China discovery and commercialization, paired with U.S.-led clinical advancement.
• China commercial portfolio centered on ETUARY, the company’s market-leading pirfenidone brand for idiopathic pulmonary fibrosis.
• FY26 ETUARY total revenue guidance set at $100.5 million-$111 million.
• Hydronidone (F351) NDA filing accepted by China’s NMPA in May 2026; potential launch targeted for early 2027.
• Pipeline priorities include targeted protein degraders and degrader-antibody conjugates, with initial IND submissions for select programs planned for Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.